Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is a top pick for potential investors due to its sustainable focus and strong performance in both its MedTech and Vision divisions. With plans to separate its Ortho business in 2027 and a promising new product launch in TECNIS PureSee, JNJ is poised for continued growth. While there are potential risks to consider, JNJ's focus on double-digit sales growth and disciplined capital allocation make it a favorable investment choice with opportunities for expansion in the Asia Pacific region.

Bears say

Johnson & Johnson is currently facing multiple challenges, including potential litigation risks related to talc products and loss of exclusivity for certain drugs. These factors could weigh on the company's financial performance in the coming years, despite its strong position in the MedTech market and a diverse portfolio of products. Additionally, the company's M&A strategy may face headwinds, as it looks to make early-stage pharmaceutical deals in a highly competitive market. These factors contribute to a negative outlook on Johnson & Johnson's stock.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.